Agile Therapeutics (AGRX) Earns “Buy” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report sent to investors on Friday. The brokerage currently has a $5.00 target price on the specialty pharmaceutical company’s stock.

AGRX has been the topic of a number of other research reports. Royal Bank of Canada reissued a buy rating and set a $10.00 price target on shares of Agile Therapeutics in a research note on Wednesday, October 18th. HC Wainwright set a $8.00 price target on Agile Therapeutics and gave the stock a buy rating in a research note on Friday. ValuEngine lowered Agile Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Finally, Janney Montgomery Scott lowered Agile Therapeutics from a buy rating to a hold rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Agile Therapeutics has an average rating of Buy and a consensus target price of $9.20.

Agile Therapeutics (NASDAQ:AGRX) traded down $2.24 during mid-day trading on Friday, reaching $2.52. The company had a trading volume of 10,344,800 shares, compared to its average volume of 408,775. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $6.70. The stock has a market cap of $45.61, a price-to-earnings ratio of -2.74 and a beta of 2.02. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. analysts anticipate that Agile Therapeutics will post -0.99 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $122,000. Royal Bank of Canada raised its position in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 27,907 shares during the period. OxFORD Asset Management LLP purchased a new position in shares of Agile Therapeutics in the 3rd quarter worth $161,000. Susquehanna International Group LLP purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $205,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $309,000. 72.92% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/25/agile-therapeutics-agrx-earns-buy-rating-from-cantor-fitzgerald.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit